Market Cap: $253.35M
OI
Ocugen, Inc.
OCGN
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $253.35M
Ocugen's Strategic Position Sparks Investor Optimism Ocugen Inc., a biotechnology firm focused on developing innovative therapies in the ocular disease space and vaccines for infectious diseases, find…
Ocugen Sees Positive Surge in Interest Following Oppenheimer Analyst Coverage Ocugen Inc. garners renewed attention in the biotechnology sector after Oppenheimer analyst Leland Gershell initiates cove…
Ocugen's Strategic Focus on Ocular Health Innovation Amidst Growing Industry Trends Ocugen (NASDAQ: OCGN) positions itself as a significant player within the biopharmaceutical landscape, particularly…
Ocugen's Strategic Advances in the Biopharmaceutical Sector In the rapidly evolving biopharmaceutical industry, Ocugen is positioning itself to capitalize on significant opportunities in the market. T…
Ocugen's Strategic Position in the Evolving Biopharmaceutical Landscape Ocugen, a biopharmaceutical company focused on innovative therapies for ocular diseases, continues to solidify its strategic pos…
Ocugen's Strategic Focus on Gene Therapy Innovations Ocugen, a biopharmaceutical company renowned for its work in gene therapies, actively drives advancements in the treatment of ocular diseases. With…
Ocugen Partners with Kwangdong Pharmaceutical to Advance OCU400 in South Korea Ocugen, Inc. has secured a significant licensing agreement with Kwangdong Pharmaceutical, granting the South Korean compa…
Ocugen Partners with Kwangdong Pharmaceutical to Boost OCU400 Development in South Korea Ocugen, Inc. solidifies its foothold in the biopharmaceutical landscape with a strategic licensing agreement wi…
Ocugen Set to Unveil Key Developments in Upcoming Earnings Report Ocugen prepares to release its quarterly earnings report on August 1, 2025, a pivotal moment for the company that operates within the…
Ocugen Prepares for Earnings Report Amid Biotech Innovations As Ocugen approaches its quarterly earnings report scheduled for August 1, 2025, the spotlight remains firmly on the company’s advancements…
Ocugen Strengthens Biopharmaceutical Portfolio Through Strategic Merger with Carisma Therapeutics Ocugen Inc. (OCGN) announces a definitive agreement to merge its subsidiary, OrthoCellix, with Carisma…
Ocugen's Strategic Merger: A Move Towards Enhanced Biopharmaceutical Capabilities Ocugen Inc. announces a definitive merger agreement between its subsidiary, OrthoCellix, and Carisma Therapeutics, mar…
FDA Approval Marks a Pivotal Moment for Ocugen’s Clinical Aspirations Ocugen Inc. announces a significant advancement in its clinical research efforts following the U.S. Food and Drug Administration's…
Ocugen Advances with FDA Clearance for Pivotal Trial of OCU410ST Ocugen Inc. secures a crucial regulatory milestone with the recent approval from the U.S. Food and Drug Administration (FDA) for its In…